METROPOLIS

Metropolis Healthcare Ltd.
Registered Office: 4th Floor, East Wing, Plot-254 B, Nirlon House, Dr. Annie Besant Rd, Worli, Mumbai - 400030, Maharashtra, India.
Corporate Office & Global Reference Laboratory: 4th Floor, Commercial Bldg-1A, Kohinoor Mall, Vidyavihar (W), Mumbai - 400 070. CIN: L73100MH2000PLC192798.

Ref: MHL/Sec&Legal/2026-27/32 **August 04, 2026**

To,

BSE Limited
Scrip Code: 542650

National Stock Exchange of India Limited
Scrip Symbol: METROPOLIS

Dear Sir/Madam,

Sub: Outcome of Board Meeting held on Tuesday, August 04, 2026

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ('SEBI Listing Regulations'), this is to inform you that the Board of Directors of the Company at its meeting held today i.e., Tuesday, August 04, 2026, approved the unaudited standalone and consolidated financial results of the Company for the quarter ended June 30, 2026, and noted the limited review report thereon, issued by the Statutory Auditors of the Company. The financial results together with the limited review report are enclosed herewith. The financial results are also being made available on the Company's website at www.metropolisindia.com.

Further, the Board of Directors noted that the sale and transfer of External Quality Assessment Services Business of the Company to Metropolis Quality Solutions Private Limited, wholly owned subsidiary of the Company, which was originally scheduled to be completed within 6 (six) months of execution of the Business Transfer Agreement dated February 04, 2026, is now expected to take an additional 2 (two) months.

The meeting commenced at 02:00 p.m. (IST) and concluded at 05:20 p.m. (IST).

You are requested to take the above information on record.

Thanking you,
Yours faithfully,

For Metropolis Healthcare Limited

Kamlesh Chandrashekhar Kulkarni

Digitally signed by Kamlesh Chandrashekhar Kulkarni
DN: c=IN, st=Maharashtra, 2.5.4.20=7b2c373c96d15b9bcfca30002f2fbd0e3a8a7775221bd4075c136f7c37ee6541, postalCode=422004, street=SO Chandrashekhar Kulkarni Plot No47 Vrundavan Nagar Dindori Road Near Gajanan Maharaj Mandir Mhasrul Nashik, pseudonym=ce57b9d646ce4631a4e68e0e138a62c3, title=1552, serialNumber=2d68a0037beac42820279c8effc9ae2073aa3f9ef35e80715cbcb9b2acfdcc68, o=Personal, cn=Kamlesh Chandrashekhar Kulkarni
Date: 2026.08.04 18:10:53 +05'30'

Kamlesh C Kulkarni
Head - Legal & Secretarial

Encl: a/a

B S R & Co. LLP

Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited standalone financial results of Metropolis Healthcare Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Metropolis Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Metropolis Healthcare Limited (hereinafter referred to as "the Company") for the quarter ended 30 June 2026 ("the Statement").

2. This Statement, which is the responsibility of the Company's management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). Our responsibility is to issue a report on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it

BSR & Co. LLP
14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai – 400 063

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

Registered Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

contains any material misstatement.

For **B S R & Co. LLP**
Chartered Accountants
Firm's Registration No.:101248W/W-100022

Rajesh Mehra
Partner
Membership No.: 103145
UDIN:26103145OOGHIR2438

Mumbai
04 August 2026

METROPOLIS

Metropolis Healthcare Limited

Registered Office: 4th Floor, East Wing, Plot 254 B, Nirlon House, Dr.Annie Besant Road, Worli, Mumbai - 400030, Maharashtra, India

CIN:L73100MH2000PLC192798

Contact No.: 8422 801 801, **Email:** support@metropolisindia.com, **Website:** www.metropolisindia.com

Global Reference Lab: 4th Floor Commercial Bldg. - 1A, Kohinoor Mall, Vidyavihar (West), Mumbai - 400070, Maharashtra, India

Statement of unaudited Standalone Financial Results for the quarter ended 30 June 2026

(Rs. in millions)

Sr. No.	Particulars	Quarter ended			Year Ended
		30 June 2026 (Unaudited)	31 March 2026 (Audited) (Refer note:2)	30 June 2025 (Unaudited)	31 March 2026 (Audited)
	Continuing operation				
1	**Income**				
	a) Revenue from operations	3,722.84	3,520.31	3,232.69	13,654.72
	b) Other income	51.86	88.17	27.79	163.31
	Total Income	**3,774.70**	**3,608.48**	**3,260.48**	**13,818.03**
2	**Expenses**				
	a) Cost of materials consumed	684.74	608.18	613.58	2,527.18
	b) Laboratory testing charges	67.68	56.90	40.55	180.18
	c) Employee benefits expense	852.43	749.28	722.69	2,974.38
	d) Finance costs	47.73	65.61	42.93	191.87
	e) Depreciation and amortisation expense	278.06	327.97	278.60	1,161.67
	f) Other expenses	1,180.30	1,204.43	1,088.29	4,590.75
	Total Expenses	**3,110.94**	**3,012.37**	**2,786.64**	**11,626.03**
3	**Profit before exceptional items and tax (1) - (2)**	663.76	596.11	473.84	2,192.00
4	**Exceptional Items (Refer note 9)**	-	-	-	79.57
5	**Profit before tax (3) - (4)**	**663.76**	**596.11**	**473.84**	**2,112.43**
6	**Tax expenses**				
	Current tax :				
	-for the period / year:	168.78	188.96	131.76	571.86
	-tax adjusted for earlier years:	-	-	3.70	3.70
	Deferred tax credit	(11.56)	(25.45)	(15.21)	(34.55)
	Total tax expenses (Net)	**157.22**	**163.51**	**120.25**	**541.01**
7	**Profit for the period / year from continuing operations (5) - (6)**	506.54	432.60	353.59	1,571.42
8	**Discontinued Operations**				
	(Loss)/Profit from discontinued operation	(0.95)	(0.33)	2.98	4.58
	Tax expense of discontinued operations	(0.24)	(0.08)	0.75	1.15
	Profit from discontinued operations (after tax)	**(0.71)**	**(0.25)**	**2.23**	**3.43**
9	**Profit for the period/year (7) + (8)**	**505.83**	**432.35**	**355.82**	**1,574.85**
10	**Other comprehensive income**				
	Items that will not be reclassified subsequently to profit and loss (net of tax)	0.44	4.41	(4.20)	(1.75)
	Items that will be subsequently reclassified to profit and loss (net of tax)	-	-	-	-
	Other comprehensive income for the period /year (net of tax)	**0.44**	**4.41**	**(4.20)**	**(1.75)**
11	**Total comprehensive income (9) + (10)**	**506.27**	**436.76**	**351.62**	**1,573.10**
12	Paid-up equity share capital (face value - Rs. 2 per share)	414.67	414.66	103.61	414.66
13	Other equity	-	-	-	13,476.40
14	**Earning per share from continuing operation**				
	Earnings per share (Face value of Rs.2 each) basic- (Rs.)*	2.44	2.09	1.72	7.60
	Earnings per share (Face value of Rs.2 each) diluted - (Rs.)*	2.44	2.09	1.71	7.60
15	**Earning per share from discontinuing operation**				
	Earnings per share (Face value of Rs.2 each) basic- (Rs.)*	(0.00)	(0.00)	0.01	0.02
	Earnings per share (Face value of Rs.2 each) diluted - (Rs.)*	(0.00)	(0.00)	0.01	0.02
16	**Earning per share from continuing and discontinuing operation**				
	Earnings per share (Face value of Rs.2 each) basic- (Rs.)*	2.44	2.09	1.73	7.62
	Earnings per share (Face value of Rs.2 each) diluted - (Rs.)*	2.44	2.09	1.72	7.62

(*not annualised for the quarters)

See accompanying notes to the unaudited standalone financial results

Metropolis Healthcare Limited Mumbai

BSR & Co. LLP 14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063

METROPOLIS

NOTES:

1 The Standalone financial results have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.

2 The figures for three months ended 31 March 2026 are arrived at as difference between audited figures in respect of full financial year ended 31 March 2026 and the unaudited published figures up to nine months ended 31 December 2025 which were subjected to review.

3 The Company has changed the presentation of financial information from Rs. in Lakhs to Rs. in Millions with effect from the quarter ended 30 June 2026. Accordingly, the comparative figures have been suitably restated in Rs. Millions for the purpose of comparability and has no impact on the profit for the period, other comprehensive income, net worth or earnings per share of any period presented

4 The Standalone financial results of the Company have been reviewed by the Audit Committee at their meeting held on 04 August 2026 and thereafter approved by the Board of Directors at their meeting held on 04 August 2026. The statutory auditors have issued unmodified review report report on the above Standalone financial results.

5 Business Acquisition :

1. Dapic Metropolis Healthcare Private Limited (formerly known as Metropolis Histoxpert Digital Services Private Limited), a wholly owned subsidiary of Metropolis Healthcare Limited ('the Company'), had entered into Business Transfer Agreement ('BTA') on 7 April 2025, with Dr. Ahujas' Pathology & Imaging Centre (DAPIC – a partnership firm), Dr. Alok Ahuja and Dr. Alka Ahuja for the acquisition of their entire businesses as a going concern on a slump sale basis. The acquisition got consummated on 23 May 2025, post-regulatory approvals, for a purchase consideration of Rs. 346.10 millions. The Company for the business acquisition had subscribed to the OCD (optionally convertible debentures) of Dapic Metropolis Healthcare Private Limited of Rs. 336.10 millions.
2. Scientific Metropolis Pathology Private Limited (formerly known as Metropolis Clinical Pathology Private Limited) ("Scientific Metropolis"), a wholly owned subsidiary of Metropolis Healthcare Limited ("the Company"), entered into a Business Transfer Agreement (BTA) on 3 March 2025, with Dr. Ashok Kumar Sharma, the sole proprietor of Dr. Ashok Kumar Sharma's Scientific Pathology, for the acquisition of the business on a slump sale basis. As part of the transaction, Dr. Ashok Kumar Sharma acquired a 10% equity stake in Scientific Metropolis, pursuant to which it ceased to be a wholly owned subsidiary of the Company. The acquisition was consummated on 16 June 2025 upon receipt of the necessary regulatory approvals. The purchase consideration was finalised at Rs. 645.00 millions (along with assumed liability of KMP remuneration) . The Company, for the business acquisition had subscribed to the OCD (optionally convertible debentures) of Scientific Metropolis of Rs. 590.31 millions .
3. On 7 August 2025, the Company entered into a Business Transfer Agreement ('BTA') with Dr. Rajendra Sadashiv Patil, sole proprietor of Dr. RS Patil's Ambika Pathology Laboratory, for the acquisition of pathology laboratories located in Kolhapur, Maharashtra, on a slump sale basis. The transaction was completed on 18 September 2025 upon receipt of the requisite regulatory approvals. The total purchase consideration was Rs. 170.00 millions.

6 During the Quarter, the Nomination and Remuneration Committee of the Company approved grant of :
a) 14,236 Restricted Stock Units (RSU) , pursuant to the Metropolis Restrictive Stock Unit Plan — 2025 to eligible employees of the Group.
b) 2,12,345 Employees Stock Options, pursuant to the Metropolis Employees Stock Option Plan — 2025 to eligible employees of the Group.
Further, in respect of Metropolis Restrictive Stock Unit Plan — 2020, 4,200 RSU's were alloted during the quarter ended 30 June 2026.

7 Based on the nature of the business and line of products/ services, there is only one reportable segment - Pathology service.

8 The Standalone financial results of the Company are available for investors at www.metropolisindia.com, www.nseindia.com and www.bseindia.com.

9 On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Company considered restructured compensation of its employees with effect from 01 April 2026, and assessed the impact of the changes, consistent with the Labour Codes, Rules, FAQs and third party's opinion. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company presented such incremental impact as "Statutory impact of new Labour Codes" under "Exceptional Items" in the statement of financial results for the quarter and year ended 31 March 2026.

10 The Company had issued and allotted 15,54,95,826 Bonus Equity Shares in the ratio of 3:1, i.e., Three (3) new fully paid-up Equity Shares of face value of INR 2/- each for every One (1) existing fully paid-up Equity Share of face value of INR 2/- each. The Board of Directors at their meeting held on 04 February 2026 approved issuance of bonus shares, which was approved by the shareholders on 08 March 2026

11 The Company had classified the External Quality Assessment Services Business division as a discontinued operation in accordance with Ind AS 105 in the financial results for the quarter and year ended March 31, 2026. Accordingly, the financial results for the quarter ended June 30, 2026 continue to present the discontinued operation separately, with the comparative figures for the quarter ended June 30, 2025 regrouped/reclassified, wherever necessary, to conform to the current period presentation. Further, the sale and transfer of the said business to Metropolis Quality Solutions Private Limited, a wholly owned subsidiary of the Company, pursuant to the Business Transfer Agreement dated February 4, 2026, is in progress and is expected to be completed in due course.

For Metropolis Healthcare Limited

Ameera Shah
Chairperson and Wholetime Director
DIN: 00208095
Place: Mumbai
Date: 04 August 2026

Metropolis Healthcare Limited Mumbai

BSR & Co. LLP
14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063

B S R & Co. LLP
Chartered Accountants

14th Floor, Central B Wing and North C Wing
Nesco IT Park 4, Nesco Center
Western Express Highway
Goregaon (East), Mumbai – 400 063, India
Telephone: +91 (22) 6257 1000
Fax: +91 (22) 6257 1010

Limited Review Report on unaudited consolidated financial results of Metropolis Healthcare Limited for the quarter ended 30 June 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Metropolis Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Metropolis Healthcare Limited (hereinafter referred to as "the Parent"), and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter ended 30 June 2026 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "*Interim Financial Reporting*" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 *"Review of Interim Financial Information Performed by the Independent Auditor of the Entity"*, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the entities mentioned in Annexure I to the Statement:

5. Attention is drawn to the fact that the figures for the three months ended 31 March 2026 as reported in the Statement are the balancing figures between audited figures in respect of the full previous financial year and the published year to date figures up to the third quarter of the previous financial year. The figures up to the end of the third quarter of previous financial year had only been reviewed and not subjected to audit.

6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 7 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

BSR & Co. LLP
14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063

B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013

Registered Office:

14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063

7. We did not review the interim financial information of two (2) Subsidiaries included in the Statement, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 555.56 millions, total net profit after tax (before consolidation adjustments) of Rs. 38.02 millions and total comprehensive income (before consolidation adjustments) of Rs. 38.88 millions, for the quarter ended 30 June 2026, as considered in the Statement. This interim financial information have been reviewed by other auditors whose reports has have been furnished to us by the Parent's management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

   Our conclusion is not modified in respect of this matter.

8. The Statement includes the interim financial information of nine (9) Subsidiaries which have not been reviewed, whose interim financial information reflects total revenues (before consolidation adjustments) of Rs. 277.72 millions, total net profit after tax (before consolidation adjustments) of Rs. 14.27 millions and total comprehensive income (before consolidation adjustments) of Rs. 14.44 millions, for the quarter ended 30 June 2026, as considered in the Statement. According to the information and explanations given to us by the Parent's management, these interim financial information are not material to the Group.

   Our conclusion is not modified in respect of this matter.

For **B S R & Co. LLP**

Chartered Accountants

Firm's Registration No.:101248W/W-100022

Rajesh Mehra

Partner

Membership No.: 103145

UDIN:26103145UQBBDP2602

Mumbai

04 August 2026

Annexure I

List of entities included in unaudited consolidated financial results.

Sr. No	Name of component	Relationship
1	Metropolis Healthcare Limited	Parent
2	Ekopath Metropolis Lab Services Private Limited	Subsidiary
3	Amin's Pathology Laboratory Private Limited	Wholly owned subsidiary
4	Centralab Healthcare Services Private Limited	Wholly owned subsidiary
5	DAPIC Metropolis Healthcare Private Limited (Formerly known as Metropolis Histoxpert Digital Services Private Limited)	Wholly owned subsidiary
6	Scientific Metropolis Pathology Private Limited (Formerly known as Metropolis Clinical Pathology Private Limited)	Subsidiary
7	Core Diagnostics Private Limited	Wholly owned subsidiary
8	Metropolis Foundation	Wholly owned subsidiary
9	Metropolis Quality Solutions Private Limited	Wholly owned subsidiary
10	Metropolis Healthcare (Mauritius) Limited	Wholly owned subsidiary
11	Metropolis Healthcare Lanka (Private) Limited	Wholly owned subsidiary
12	Metropolis Bramser Lab Services (Mtlus) Limited	Wholly owned subsidiary
13	Metropolis Healthcare (Tanzania) Limited	Wholly owned subsidiary
14	Metropolis Healthcare Ghana Limited	Wholly owned subsidiary
15	Metropolis Star Lab Kenya Limited	Wholly owned subsidiary
16	Metropolis Healthcare Uganda Limited	Wholly owned subsidiary

BSR & Co. LLP
14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063

METROPOLIS

Metropolis Healthcare Limited

Registered Office: 4th Floor, East Wing, Plot 254 B, Nirlon House, Dr.Annie Besant Road, Worli, Mumbai - 400030, Maharashtra, India

CIN:L73100MH2000PLC192798

Contact No.: 8422 801 801, **Email:** support@metropolisindia.com, **Website:** www.metropolisindia.com

Global Reference Lab: 4th Floor Commercial Bldg. - 1A, Kohinoor Mall, Vidyavihar (West), Mumbai - 400070, Maharashtra, India

Statement of unaudited Consolidated Financial Results for the quarter ended 30 June 2026

(Rs. in millions)

Sr. No.	Particulars	Quarter ended			Year Ended
		30 June 2026 (Unaudited)	31 March 2026 (Audited) (Refer note:2)	30 June 2025 (Unaudited)	31 March 2026 (Audited)
1	**Income**				
	a) Revenue from operations	4,502.15	4,246.82	3,860.63	16,458.46
	b) Other income	51.02	81.62	75.16	255.84
	Total Income	**4,553.17**	**4,328.44**	**3,935.79**	**16,714.30**
2	**Expenses**				
	a) Cost of materials consumed	871.01	784.82	790.49	3,245.17
	b) Laboratory testing charges	63.30	43.07	56.74	230.05
	c) Employee benefits expense	1,069.76	954.67	922.79	3,773.65
	d) Finance costs	61.80	79.33	51.98	245.44
	e) Depreciation and amortisation expense	324.03	385.90	308.45	1,337.22
	f) Other expenses	1,386.15	1,384.08	1,193.04	5,201.14
	Total Expenses	**3,776.05**	**3,631.87**	**3,323.49**	**14,032.67**
3	**Profit before exceptional items and tax (1) - (2)**	**777.12**	**696.57**	**612.30**	**2,681.63**
4	**Exceptional items (Refer note 10)**	-	(1.07)	-	89.90
5	**Profit before tax (3) - (4)**	**777.12**	**697.64**	**612.30**	**2,591.73**
6	**Tax expenses**				
	Current tax:				
	- for the year :	210.36	224.74	172.61	733.22
	- tax adjusted for earlier years :	(0.16)	-	3.70	3.70
	Deferred tax credit	(1.91)	(36.71)	(16.46)	(56.98)
	Total tax expenses	**208.29**	**188.03**	**159.85**	**679.94**
7	**Profit for the period / year (5) –(6)**	**568.83**	**509.61**	**452.45**	**1,911.79**
8	**Other comprehensive income**				
	Items that will not be reclassified subsequently to profit and loss (net of tax)	1.29	3.72	(4.42)	4.10
	Items that will be subsequently reclassified to profit and loss (net of tax)	26.95	29.82	(17.37)	44.10
	Other comprehensive income for the period /year (net of tax)	**28.24**	**33.54**	**(21.79)**	**48.20**
9	**Total comprehensive income (7) + (8)**	**597.07**	**543.15**	**430.66**	**1,959.99**
10	**Profit attributable to:**				
	Owners of the Company	566.67	509.05	450.60	1,900.17
	Non-controlling interest	2.16	0.56	1.85	11.62
11	**Other comprehensive income attributable to:**				
	Owners of the Company	28.23	33.47	(21.80)	48.17
	Non-controlling interest	0.01	0.07	0.01	0.03
12	**Total comprehensive income attributable to:**				
	Owners of the Company	594.90	542.52	428.80	1,948.34
	Non-controlling interest	2.17	0.63	1.86	11.65
13	Paid-up equity share capital (face value - Rs. 2 per share)	414.67	414.66	103.61	414.66
14	Other equity (including Non-controlling interest)	-	-	-	14,716.95
15	Earnings per share (Face value of Rs.2 each) basic-	2.73	2.46	2.17	9.19
	Earnings per share (Face value of Rs.2 each) diluted - (Rs.)*	2.73	2.46	2.17	9.19

(*not annualised for the quarters)

See accompanying notes to the unaudited consolidated financial results

Metropolis Healthcare Limited ★ Mumbai

BSR & Co. LLP
14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063

METROPOLIS

NOTES:

1 Metropolis Healthcare Limited (the 'Company' or the 'Parent') and its subsidiaries (referred collectively as the 'Group') are primarily involved in providing pathology and related healthcare services.

2 The figure for three months ended 31 March 2026 are arrived at as difference between audited figures in respect of full financial year end and the unaudited published figures upto nine months ended 31 December 2025 respectively which was subjected to review.

3 The Group has changed the presentation of financial information from Rs. in Lakhs to Rs. in Millions with effect from the quarter ended 30 June 2026. Accordingly, the comparative figures have been suitably restated in Rs. Millions for the purpose of comparability and has no impact on the profit for the period, other comprehensive income, net worth or earnings per share of any period presented

4 The Consolidated financial results for the quarter ended 30 June 2026 (Consolidated financial results) have been prepared in accordance with the recognition and measurement principles of Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India.

5 The Consolidated financial results of the Group have been reviewed by the Audit Committee at their meeting held on 04 August 2026 and thereafter approved by the Board of Directors at their meeting held on 04 August 2026. The statutory auditors have issued unmodified review report on the above Consolidated financial results.

6 Business Acquisition :

1. Dapic Metropolis Healthcare Private Limited (formerly known as Metropolis Histoxpert Digital Services Private Limited), a wholly owned subsidiary of Metropolis Healthcare Limited ('the Company'), had entered into Business Transfer Agreement ('BTA') on 7 April 2025, with Dr. Ahujas' Pathology & Imaging Centre (DAPIC – a partnership firm). Dr. Alok Ahuja and Dr. Alka Ahuja for the acquisition of their entire businesses as a going concern on a slump sale basis. The acquisition got consummated on 23 May 2025, post-regulatory approvals, for a purchase consideration of Rs.346.10 millions.

2. Scientific Metropolis Pathology Private Limited (formerly known as Metropolis Clinical Pathology Private Limited) ("Scientific Metropolis"), a wholly owned subsidiary of Metropolis Healthcare Limited ("the Company"), entered into a Business Transfer Agreement (BTA) on 03 March 2025, with Dr. Ashok Kumar Sharma, the sole proprietor of Dr. Ashok Kumar Sharma's Scientific Pathology, for the acquisition of the business on a slump sale basis. As part of the transaction, Dr. Ashok Kumar Sharma acquired a 10% equity stake in Scientific Metropolis, pursuant to which it ceased to be a wholly owned subsidiary of the Company. The acquisition was consummated on 16 June 2025 upon receipt of the necessary regulatory approvals. The purchase consideration was finalised at Rs. 645.00 millions (along with assumed liability of KMP remuneration). The Company, for the business acquisition had subscribed to the OCD (optionally convertible debentures) of Scientific Metropolis of Rs. 590.31 millions.

3. On 07 August 2025, the Company entered into a Business Transfer Agreement ('BTA') with Dr. Rajendra Sadashiv Patil, sole proprietor of Dr. RS Patil's Ambika Pathology Laboratory, for the acquisition of pathology laboratories located in Kolhapur, Maharashtra, on a slump sale basis. The transaction was completed on 18 September 2025 upon receipt of the requisite regulatory approvals. The total purchase consideration was Rs 170.00 millions.

7 During the Quarter, the Nomination and Remuneration Committee of the Company approved grant of :
a) 14,236 Restricted Stock Units (RSU) , pursuant to the Metropolis Restrictive Stock Unit Plan — 2025 to eligible employees of the Group.
b) 2,12,345 Employees Stock Options, pursuant to the Metropolis Employees Stock Option Plan — 2025 to eligible employees of the Group.
Further, in respect of Metropolis Restrictive Stock Unit Plan — 2020, 4,200 RSU's were alloted during the quarter ended 30 June 2026.

8 Based on the nature of the business and line of products/ services, there is only one reportable segment - Pathology service.

9 The Consolidated financial results of the Group are available for investors at www.metropolisindia.com, www.nseindia.com and www.bseindia.com.

10 On 21 November 2025, the Government of India notified the four Labour Codes - the Code on Wages, 2019, the Industrial Relations Code, 2020, the Code on Social Security, 2020, and the Occupational Safety, Health and Working Conditions Code, 2020 - consolidating 29 existing labour laws. The Company considered restructured compensation of its employees with effect from 01 April 2026, and assessed the impact of the changes, consistent with the Labour Codes, Rules, FAQs and third party's opinion. Considering the materiality and regulatory-driven, non-recurring nature of this impact, the Company presented such incremental impact as "Statutory impact of new Labour Codes" under "Exceptional Items" in the statement of financial results for the quarter and year ended 31 March 2026.

11 The Company had issued and allotted 15,54,95,826 Bonus Equity Shares in the ratio of 3:1, i.e., Three (3) new fully paid-up Equity Shares of face value of INR 2/- each for every One (1) existing fully paid-up Equity Share of face value of INR 2/- each. The Board of Directors at their meeting held on 04 February 2026 approved issuance of bonus shares,which was approved by the shareholders on 08 March 2026.

For Metropolis Healthcare Limited

Ameera Shah
Chairperson and Wholetime Director
DIN: 00208095
Place: Mumbai
Date: 04 August 2026

Metropolis Healthcare Limited
Mumbai

BSR & Co. LLP
14th Floor, Central B Wing and North C Wing, Nesco IT Park4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400 063